First Horizon Advisors’s Vaxcyte PCVX Stock Holding History

First Horizon Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$9.13K	Sell	281 -134	-32%	-$4.39K	﹤0.01%	1705
2025 Q1	$15.7K	Buy	415 +268	+182%	+$21.4K	﹤0.01%	1430
2024 Q4	$12K	Sell	147 -410	-74%	-$40.7K	﹤0.01%	1520
2024 Q3	$63.6K	Sell	557 -85	-13%	-$7.66K	﹤0.01%	880
2024 Q2	$48.5K	Sell	642 -100	-13%	-$6.81K	﹤0.01%	934
2024 Q1	$50.7K	Sell	742 -65	-8%	-$4.5K	﹤0.01%	936
2023 Q4	$50.7K	Hold	807	–	–	﹤0.01%	935
2023 Q3	$41.1K	Buy	807 +45	+6%	+$2.22K	﹤0.01%	932
2023 Q2	$38.1K	Buy	762 +727	+2,077%	+$34.5K	﹤0.01%	1007
2023 Q1	$1.31K	Hold	35	–	–	﹤0.01%	2199
2022 Q4	$1.68K	Buy	+35	New	+$1.37K	﹤0.01%	2108

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

First Horizon Advisors's PCVX Position: Q2 2025 in Review

First Horizon Advisors reduced its Vaxcyte (PCVX) stake by 32% in Q2 2025, selling an estimated $4.39K and leaving 281 shares worth $9.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1705.

First Horizon Advisors first reported a position in PCVX in Q4 2022 and has held it in 11 quarters since. The position peaked at $63.6K in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

First Horizon Advisors held 281 shares of Vaxcyte worth $9.13K as of Q2 2025.
First Horizon Advisors sold 134 Vaxcyte shares in Q2 2025, an estimated $4.39K.
Vaxcyte made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1705 holding.
First Horizon Advisors first reported a position in Vaxcyte in Q4 2022 and has held it in 11 quarters since.
First Horizon Advisors's Vaxcyte position peaked at $63.6K in Q3 2024.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.